Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.
Paola Queirolo
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Francesco Spagnolo
No relevant relationships to disclose
Maresa Altomonte
No relevant relationships to disclose
Vanna Chiarion-Sileni
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Roche
Jacopo Pigozzo
No relevant relationships to disclose
Michele Del Vecchio
No relevant relationships to disclose
Lorenza Di Guardo
No relevant relationships to disclose
Ruggero Ridolfi
No relevant relationships to disclose
Alessandro Scoppola
No relevant relationships to disclose
Pier Francesco Ferrucci
Consultant or Advisory Role - Delcath Systems
Honoraria - Delcath Systems
Virginia Ferraresi
No relevant relationships to disclose
Maria Grazia Bernengo
Consultant or Advisory Role - Bristol-Myers Squibb
Michele Guida
No relevant relationships to disclose
Riccardo Marconcini
No relevant relationships to disclose
Mario MandalĂ
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline
Giorgio Parmiani
Consultant or Advisory Role - CureVac
Other Remuneration - Recombio
Gaetana Rinaldi
No relevant relationships to disclose
Massimo Aglietta
No relevant relationships to disclose
Ester Simeone
No relevant relationships to disclose
Paolo Antonio Ascierto
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; MedImmune; MSD; Novartis; Roche/Genentech
Honoraria - Bristol-Myers Squibb; MSD; Roche/Genentech